Viking Therapeutics, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Viking Therapeutics, Inc. now
Current reporting with the operating signal separated from the noise.
Viking Therapeutics, Inc. (VKTX) Q2 2026 Earnings Call Transcript
Investors are testing whether Viking Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Viking Therapeutics, Inc. (VKTX) stock falls amid market uptick: What investors need to know
Investors are testing whether Viking Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity
The development tests whether Viking Therapeutics, Inc. can turn product investment into adoption, revenue and durable advantage.
Watch next: confirmation in a company filing, official release or regulator record.Viking Therapeutics, Inc. (VKTX) Q3 2025 Earnings Call Transcript
Investors are testing whether Viking Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Latest VKTX filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Viking Therapeutics, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
SEARCH Q2 COVERAGE →Third quarter
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →